A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
NCT05482087
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
190
Enrollment
INDUSTRY
Sponsor class
Conditions
ALK-positive NSCLC
Interventions
DRUG:
XZP-3621
Sponsor
Xuanzhu Biopharmaceutical Co., Ltd.